Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Cantor Fitzgerald
Deloitte
QuintilesIMS
Daiichi Sankyo
Federal Trade Commission
McKinsey
Accenture
Teva
Citi

Generated: October 22, 2017

DrugPatentWatch Database Preview

BELSOMRA Drug Profile

« Back to Dashboard

Which patents cover Belsomra, and when can generic versions of Belsomra launch?

Belsomra is a drug marketed by Merck Sharp Dohme and is included in one NDA. There is one patent protecting this drug.

This drug has fifty-four patent family members in thirty-five countries.

The generic ingredient in BELSOMRA is suvorexant. One supplier is listed for this compound. Additional details are available on the suvorexant profile page.

Summary for Tradename: BELSOMRA

US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list36
Clinical Trials: see list13
Patent Applications: see list19
Drug Prices:see details
DailyMed Link:BELSOMRA at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
BELSOMRA
suvorexant
TABLET;ORAL204569-001Aug 13, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
Merck Sharp Dohme
BELSOMRA
suvorexant
TABLET;ORAL204569-004Aug 13, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Merck Sharp Dohme
BELSOMRA
suvorexant
TABLET;ORAL204569-002Aug 13, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
BELSOMRA
suvorexant
TABLET;ORAL204569-004Aug 13, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
BELSOMRA
suvorexant
TABLET;ORAL204569-001Aug 13, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
BELSOMRA
suvorexant
TABLET;ORAL204569-002Aug 13, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
Merck Sharp Dohme
BELSOMRA
suvorexant
TABLET;ORAL204569-003Aug 13, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
BELSOMRA
suvorexant
TABLET;ORAL204569-003Aug 13, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: BELSOMRA

Country Document Number Estimated Expiration
Cyprus1113798► Subscribe
EcuadorSP099374► Subscribe
South Korea20100031767► Subscribe
Russian Federation2458924► Subscribe
China101627028► Subscribe
Australia2010249269► Subscribe
New Zealand577334► Subscribe
Argentina063979► Subscribe
Israel198825► Subscribe
Taiwan201109318► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Julphar
Chubb
Federal Trade Commission
UBS
Merck
Citi
McKinsey
Moodys
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot